Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price

Sangamo Therapeutics (NASDAQ:SGMO) had its price target trimmed by Barclays from $9.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other brokerages have also commented on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, April 7th. Finally, Truist Financial reduced their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.50.

Sangamo Therapeutics Trading Down 4.8%

SGMO stock opened at $0.44 on Wednesday. The stock has a market cap of $100.39 million, a P/E ratio of -0.58 and a beta of 1.46. The stock’s fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $1.34. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the stock. E Fund Management Co. Ltd. bought a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at $25,000. JPMorgan Chase & Co. grew its holdings in Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 25,000 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter worth about $28,000. Finally, Shelton Wealth Management LLC purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter worth about $29,000. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.